{"disease":{"id":"chronic-urticaria","name":"chronic urticaria"},"drugs":{"marketed":[{"drug_id":"omalizumab","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xolair","generic_name":"omalizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Ig epsilon chain C region","drug_class":"Anti-IgE [EPC]","quality_score":52,"revenue":"3200","mechanism":null},{"drug_id":"fexofenadine","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Allegra","generic_name":"fexofenadine","company_name":"Generic (originally Hoechst Marion Roussel/Sanofi)","drug_phase":"marketed","molecular_target":"Solute carrier organic anion transporter family member 1A2, Multidrug resistance protein 1, Histamine H1 receptor","drug_class":"Second-generation antihistamine","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"terfenadine","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Seldane","generic_name":"TERFENADINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"High Risk QT Prolonging Agents","quality_score":32,"revenue":null,"mechanism":""},{"drug_id":"astemizole","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hismanal","generic_name":"ASTEMIZOLE","company_name":"","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"High Risk QT Prolonging Agents","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"cetirizine","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zyrtec","generic_name":"cetirizine","company_name":"Generic (originally UCB Pharma)","drug_phase":"marketed","molecular_target":"Angiopoietin-1 receptor, Histamine H1 receptor, Potassium voltage-gated channel subfamily H member 2","drug_class":"Second-generation antihistamine","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"xolair","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xolair","company_name":"Taizhou Mabtech Pharmaceutical Co.,Ltd","drug_phase":"marketed","molecular_target":"Ig epsilon chain C region","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"desloratadine","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Clarinex","generic_name":"desloratadine","company_name":"Generic (originally Schering-Plough/MSD)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, Histamine H4 receptor, Multidrug resistance protein 1","drug_class":"Histamine-1 Receptor Antagonist [EPC]","quality_score":54,"revenue":null,"mechanism":"Active metabolite of loratadine with higher potency at H1 receptors and additional anti-inflammatory properties."},{"drug_id":"loratadine","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Claritin","generic_name":"loratadine","company_name":"Generic (originally Schering-Plough)","drug_phase":"marketed","molecular_target":"Sodium-dependent neutral amino acid transporter B(0)AT2, Cytochrome P450 2C19, Multidrug resistance protein 1","drug_class":"Second-generation antihistamine","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"ebastine","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bastel","generic_name":"EBASTINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"ebastine","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe chronic spontaneous urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe chronic spontaneous urticaria in infants and children","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"levocetirizine","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xyzal","generic_name":"LEVOCETIRIZINE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Histamine-1 Receptor Antagonist","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"desloratadin","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Desloratadin","company_name":"Max Zeller Soehne AG","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, Histamine H4 receptor, Multidrug resistance protein 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":13,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07450170","title":"A Real-World Study of Omalizumab Treatment Patterns in Chronic Urticaria Patients in China","phase":"","overall_status":"COMPLETED","enrollment_count":3485,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07358364","title":"Remibrutinib in Real-world Clinical Practice","phase":"","overall_status":"RECRUITING","enrollment_count":3280,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03580356","title":"A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1078,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03580369","title":"A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1072,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04210843","title":"Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1033,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT07021495","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","phase":"","overall_status":"RECRUITING","enrollment_count":840,"lead_sponsor_name":"Leiden University Medical Center","has_results":false},{"nct_id":"NCT04584190","title":"Real Life Use of Omalizumab in Chronic Urticaria","phase":"","overall_status":"UNKNOWN","enrollment_count":700,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT05513001","title":"An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":696,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04426890","title":"To Compare Efficacy and Safety of CT-P39 and EU-approved Xolair in Patients With Chronic Spontaneous Urticaria","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":634,"lead_sponsor_name":"Celltrion","has_results":true},{"nct_id":"NCT04976192","title":"Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":608,"lead_sponsor_name":"Teva Pharmaceuticals USA","has_results":true},{"nct_id":"NCT05774639","title":"Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"Kashiv BioSciences, LLC","has_results":false},{"nct_id":"NCT07358780","title":"Remibrutinib in Real-world Clinical Practice - a US Sub-study","phase":"","overall_status":"RECRUITING","enrollment_count":505,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02626221","title":"A Worldwide Antihistamine-Refractory Chronic Urticaria Patient Evaluation in Latin America and Canada (AWARE-LACan)","phase":"","overall_status":"COMPLETED","enrollment_count":497,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06042478","title":"Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":470,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05030311","title":"A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":470,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05032157","title":"A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":455,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06396026","title":"A Study of Efficacy and Safety of TLL-018 in CSU Participants","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":436,"lead_sponsor_name":"Hangzhou Highlightll Pharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT03328897","title":"Study of Efficacy and Safety of Xolair® (Omalizumab) in Chinese Patients With Chronic Spontaneous Urticaria","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":418,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06063044","title":"Food-specific IgG4-guided Elimination Diets Improve Allergy Symptoms in Children","phase":"","overall_status":"COMPLETED","enrollment_count":407,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT07316114","title":"A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT06868212","title":"A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04180488","title":"Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":397,"lead_sponsor_name":"Sanofi","has_results":true},{"nct_id":"NCT06365879","title":"To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":392,"lead_sponsor_name":"Taizhou Mabtech Pharmaceutical Co.,Ltd","has_results":false},{"nct_id":"NCT02477332","title":"Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":382,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05976243","title":"A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":362,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07408219","title":"A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients","phase":"","overall_status":"RECRUITING","enrollment_count":350,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02161562","title":"OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":314,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03926611","title":"This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":311,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06250400","title":"Efficacy and Safety of Histamine Human Immunoglobulin in the Treatment of Chronic Spontaneous Urticaria (CSU)","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":252,"lead_sponsor_name":"Hangzhou Grand Biologic Pharmaceutical, Inc.","has_results":false},{"nct_id":"NCT04109313","title":"An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":229,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02649218","title":"A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":226,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05368285","title":"A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":208,"lead_sponsor_name":"Celldex Therapeutics","has_results":false},{"nct_id":"NCT06228560","title":"Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":202,"lead_sponsor_name":"Longbio Pharma","has_results":false},{"nct_id":"NCT07328178","title":"Analysis of the Role of IgE Proteoforms in Health and Disease","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"KU Leuven","has_results":false},{"nct_id":"NCT07219615","title":"A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT05405660","title":"A Study of CDX-0159 in Patients With Chronic Inducible Urticaria","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":196,"lead_sponsor_name":"Celldex Therapeutics","has_results":false},{"nct_id":"NCT04833855","title":"Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":183,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT07402213","title":"Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":180,"lead_sponsor_name":"Jemincare","has_results":false},{"nct_id":"NCT02435238","title":"AWARE - Chronic Urticaria","phase":"","overall_status":"COMPLETED","enrollment_count":180,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05107115","title":"Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":161,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT04612725","title":"A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":159,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT07415551","title":"Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Yuhan Corporation","has_results":false},{"nct_id":"NCT06864507","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HS-10561 Capsule in Healthy Chinese Adults and Patients With Chronic Spontaneous Urticaria.","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":150,"lead_sponsor_name":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05795153","title":"A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":144,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02550106","title":"Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":136,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06072157","title":"Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":136,"lead_sponsor_name":"Allakos Inc.","has_results":false},{"nct_id":"NCT05936567","title":"Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":136,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT06509334","title":"Trial of JYB1904 in Chronic Spontaneous Urticaria.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":135,"lead_sponsor_name":"Jemincare","has_results":false},{"nct_id":"NCT00783354","title":"A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Study P03147)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":129,"lead_sponsor_name":"Organon and Co","has_results":false},{"nct_id":"NCT05528861","title":"A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":127,"lead_sponsor_name":"Allakos Inc.","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}